NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 200 filers reported holding NEKTAR THERAPEUTICS in Q2 2017. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $283,000 | +12.7% | 4,645 | -9.8% | 0.23% | +7.5% |
| Q2 2018 | $251,000 | -49.8% | 5,147 | +9.3% | 0.21% | -51.4% |
| Q1 2018 | $500,000 | -12.6% | 4,709 | -50.9% | 0.44% | -7.4% |
| Q4 2017 | $572,000 | +129.7% | 9,582 | -7.6% | 0.48% | +117.9% |
| Q3 2017 | $249,000 | +20.9% | 10,367 | -1.8% | 0.22% | +19.1% |
| Q2 2017 | $206,000 | -19.5% | 10,553 | -3.1% | 0.18% | -19.4% |
| Q1 2017 | $256,000 | +36.2% | 10,890 | -28.9% | 0.23% | +34.3% |
| Q4 2016 | $188,000 | -27.1% | 15,322 | +1.9% | 0.17% | -30.2% |
| Q3 2016 | $258,000 | +19.4% | 15,043 | -0.7% | 0.24% | +14.2% |
| Q2 2016 | $216,000 | +3.8% | 15,146 | +0.1% | 0.21% | +2.9% |
| Q1 2016 | $208,000 | -25.2% | 15,136 | -8.3% | 0.21% | -18.6% |
| Q4 2015 | $278,000 | +57.1% | 16,514 | +2.3% | 0.25% | +31.8% |
| Q3 2015 | $177,000 | -9.7% | 16,139 | +2.8% | 0.19% | -0.5% |
| Q2 2015 | $196,000 | +32.4% | 15,699 | +16.3% | 0.19% | +33.1% |
| Q1 2015 | $148,000 | -24.5% | 13,500 | +7.0% | 0.14% | -23.3% |
| Q4 2014 | $196,000 | – | 12,616 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |